Table I.
Pembrolizumab n = 23 |
|
---|---|
Objective response rate, n (%) [95% CI] | 3 (13·0) [2·8–33·6] |
Best objective response, n (%) | |
Complete response | 1 (4·3) |
Partial response | 2 (8·7) |
Stable disease | 1 (4·3) |
Progressive disease | 11 (47·8) |
No assessment a | 8 (34·8) |
CI, confidence interval.
Patients with no assessment either died or discontinued the study without having had imaging performed.